Clinical trials recruiting for Refractory Cancer
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| New York | 3 |
| California | 2 |
| Colorado | 2 |
| Florida | 2 |
| Massachusetts | 2 |
| Michigan | 2 |
| Ohio | 2 |
| Texas | 2 |
| Virginia | 2 |
| Connecticut | 1 |
| Illinois | 1 |
| Indiana | 1 |
Top cities
Self-screener
Recruiting trials
- A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
- Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
- Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Related conditions
Trials recruiting for Refractory Cancer often also study these conditions. Each links to its own recruiting-trial list.
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Refractory Cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.